Aurora Spine reached a sales milestone in the third quarter, according to financial results posted Nov. 16.
Four things to know:
1. The company's $2.9 million third-quarter revenue was a 22.1 percent increase year over year, according to a news release. It's the second highest quarterly revenue in the company's history and the highest level in more than two years.
2. Sixty-nine percent of sales were Aurora's proprietary products in the third quarter, and in September alone, 75 percent of sales were proprietary.
3. Aurora advanced its Dexa-C technology and received FDA clearance for it in the third quarter. The spine implants are designed to match a patient's bone density. Aurora Spine is working to secure its use in an initial surgery before the end of 2021.
4. "I think the company has several opportunities to build upon the revenue levels generated in the third quarter," Trent Northcutt, Aurora Spine president and CEO, said in the release "The successful capital raise in the quarter will allow the company to deliver on the high interest in our proprietary products as well as add key personnel to get Aurora products into more doctors' hands."